Abstracts Archive - Page 2578 of 2607 - ACR Meeting Abstracts

Abstract Number: 378 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Nicole M. Engel-Nitz¹, Sarika Ogale² and Mahesh Kulakodlu¹, ¹Observational Research, OptumInsight, Eden Prairie, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Studies have shown better response for anti-TNFs (aTNF) when they are used in combination with non-biologic DMARDs (nbDMARD), than when used as monotherapies.1 Therefore,…
Abstract Number: 379 • 2012 ACR/ARHP Annual Meeting
Persistency and Predictors of Persistency of Adalimumab Among Rheumatoid Arthritis (RA) Patients in a US Registry
Allan Gibofsky¹, Katherine C. Saunders², Arijit Ganguli³, Mary Cifaldi⁴, Shannon Grant⁵, Jerry Clewell⁴, Neelufar Mozaffarian⁴, James Shaw⁶, Reva McCaskill⁴, George W. Reed⁷ and Jeffrey D. Greenberg⁸, ¹Medicine and Public Health, Hospital for Special Surgery, New York, NY, ²Corrona, LLC., Southborough, MA, ³AbbVie, North Chicago, IL, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Axio Research LLC, Seattle, WA, ⁶Global Health Economics and Outcomes Research, Abbott, Abbott Park, IL, ⁷University of Massachusetts Medical School, Worcester, MA, ⁸Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: There are limited observational data to guide physician decision-making when choosing to begin a patient on a new biologic treatment. Understanding real-world trends in…
Abstract Number: 380 • 2012 ACR/ARHP Annual Meeting
DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry
John J. Cush¹, George Reed², Katherine C. Saunders³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Arthur Kavanaugh⁶, ¹Baylor Research Institute, Dallas, TX, ²Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: CORRONA is a nationwide longitudinal disease-based registry that includes 32875 rheumatoid (RA) and 5462 psoriatic arthritis (PsA) patients. We sought to ascertain the frequency…
Abstract Number: 381 • 2012 ACR/ARHP Annual Meeting
DAS Does Not Predict Increasing Treatment in Early Rheumatoid Arthritis: Results From the CATCH Study
Lonnie Pyne¹, Vivian P. Bykerk², Carol A. Hitchon³, Edward Keystone⁴, J. Carter Thorne⁵, Boulos Haraoui⁶, Ashley Bonner⁷, Janet E. Pope⁸ and CATCH Investigators⁹, ¹Western University, London, ON, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁹Toronto, ON, Canada
Background/Purpose: The disease activity score (DAS) was developed in RA to guide therapy. Its utility in practice for early rheumatoid arthritis (ERA) has not been…
Abstract Number: 382 • 2012 ACR/ARHP Annual Meeting
Does Biased Risk Perception Explain the Underuse of Disease Modifying Anti-Rheumatic Drugs?
Richard W. Martin¹, Andrew J. Head², James D. Birmingham³ and Aaron T. Eggebeen¹, ¹Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ²Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ³Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: The prescription of a Disease Modifying Anti-rheumatic Drugs (DMARD) for patients with rheumatoid arthritis (RA) is considered a standard of effective care. However a…
Abstract Number: 383 • 2012 ACR/ARHP Annual Meeting
2002-04 Vs.2007-09: Initiation of Combination, and Tapering/Discontinuation (DC) Patterns of TNFi and MTX in a US (RA) Patient Registry: Analysis with CDAI Scores
Deborah Wenkert¹, Shannon Grant², David H. Collier³, Andrew S. Koenig⁴ and Joel M. Kremer⁵, ¹Inflammation TA, Amgen Inc., Thousand Oaks, CA, ²Axio Research LLC, Seattle, WA, ³Amgen Inc., Thousand Oaks, CA, ⁴Specialty Care, Pfizer Inc, Collegeville, PA, ⁵Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: We compared patient (pt) characteristics, for initiating, tapering and DC of TNFi/MTX combination therapy (CT), among RA pts seen during 02-04 vs. 07-09 to…
Abstract Number: 384 • 2012 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: A Canadian Patient Survey
Boulos Haraoui¹, William G. Bensen², J. Carter Thorne³, John P. Wade⁴, Melissa Deamude⁵, Jane M. Prince⁶ and Jean Legare⁷, ¹Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ²Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ⁶Vancouver Arthritis Centre, Vancouver Coastal Health, Vancouver, BC, Canada, ⁷Arthritis Alliance of Canada, Montreal, QC, Canada
Background/Purpose: Recently, many countries, including Canada, evaluated rheumatologists’ acceptance and agreement with a set of 10 Treat to Target (T2T) recommendations for rheumatoid arthritis (RA),…
Abstract Number: 385 • 2012 ACR/ARHP Annual Meeting
The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis – There Is Need for Guidelines
A. Bharadwaj¹ and Carol Alves², ¹Rheumatology, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom, ²Research & Development, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which causes significant pain and swelling in the joints. The early treatment of the disease mainly…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 387 • 2012 ACR/ARHP Annual Meeting
Medication Choices and Medication Survival in a National Multicentre Community Based Rheumatoid Arthritis Cohort
Lynden Roberts¹, Kathleen Tymms², Julien P. de Jager³, Geoffrey O. Littlejohn⁴, Hedley Griffiths⁵, Dave Nicholls⁶, Paul Bird⁷, Julie Hill⁸, Philip McCloud⁸, James C. Scott⁹, Jane Zochling¹⁰ and OPAL Consortium¹¹, ¹School of Medicine, James Cook University, Townsville, Australia, ²Canberra Rheumatology, Canberra, ACT, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Rheumatology, Monash Medical Center, Melbourne, Australia, ⁵Barwon Rheumatology Service, Geelong, Australia, ⁶Coast Joint Care, Maroochydore, Australia, ⁷Combined Rheumatology Practice, Sydney, Australia, ⁸Statistics, McCloud Consulting Group, Sydney, Australia, ⁹Medical Affairs, Roche Products Pty Limited, Sydney, Australia, ¹⁰Menzies Research Institute Tasmania, Hobart, Australia, ¹¹Melbourne, Australia
Background/Purpose: A sizeable body of high-quality research underpins our knowledge of the efficacy of various RA therapies. Outside the controlled environment of these clinical trials,…
Abstract Number: 388 • 2012 ACR/ARHP Annual Meeting
Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry
Chi Chiu Mok¹, Cherry Kwan¹, Helen Chan², Ka Lai Lee³ and Lai-Shan Tam⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Rehabilitation, Kowloon Hospital, Hong Kong, Hong Kong, Hong Kong, ³Medicine, Pamela Youde Eastern Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: To study the retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and the associated factors for drug withdrawal Methods: Data…
Abstract Number: 389 • 2012 ACR/ARHP Annual Meeting
Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy – an Administrative Claims Database Analysis
Stephen Johnston¹, Tripthi Kamath², Nianwen Shi³, Robert Fowler³, Bong-Chul Chu³ and William Reiss⁴, ¹Truven Health Analytics, Bethesda, MD, ²Genentech, South San Francisco, CA, ³Truven Health Analytics, Washington, DC, ⁴Genentech Inc., South San Francisco, CA
Background/Purpose: The current treatment paradigm in RA is to attempt to decrease concomitant use of oral glucocorticoids (OGC). This study examined the OGC-sparing effects of…
Abstract Number: 350 • 2012 ACR/ARHP Annual Meeting
Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results From Prospective Cohort Studies
Inge A.M. van den Oever and Mike T. Nurmohamed, Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of heart failure (HF). The chronic inflammatory state in RA is associated with increased levels of…
Abstract Number: 351 • 2012 ACR/ARHP Annual Meeting
Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry –RoAcTEmra)
Jacques Morel¹, Marie-Odile Duzanski², Thomas Bardin³, Alain G. Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, Rene-Marc Flipo⁷, Jacques-Eric Gottenberg⁸, Xavier Mariette⁹, Martin Soubrier¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³ and Jean Sibilia¹⁴, ¹Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹¹Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ¹²Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France
Background/Purpose: To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods: The French Society of Rheumatology and the…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].